AI Article Synopsis

  • This study is a follow-up on the effectiveness and safety of tazemetostat for Japanese patients with relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) who have the EZH2 mutation, after a median follow-up of 35 months.
  • The FL cohort had an impressive objective response rate of 70.6%, with significant progression-free survival (PFS) rates at 24 and 36 months (72.1% and 64.1% respectively), while no unexpected severe adverse events were reported.
  • Overall, long-term treatment with tazemetostat appears to be a promising and safe option as a third-line or later therapy for patients with this specific

Article Abstract

Previously, we reported the efficacy and safety of tazemetostat in Japanese patients with relapsed/refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) harboring the EZH2 mutation in a multicenter, open-label, phase II study. Here, we present a follow-up analysis of tazemetostat at a long-term median follow-up of 35.0 months. Twenty patients were enrolled: 17 in the FL cohort and three in the DLBCL cohort. In the FL cohort, the objective response rate was 70.6%, consistent with the primary analysis, and the median progression-free survival (PFS) was not reached. The 24-month and 36-month PFS rates were 72.1% (95% confidence interval [CI] 41.5%-88.6%) and 64.1% (95% CI 33.7%-83.4%), respectively. The median duration of treatment was 30.2 months. After the primary analysis at a median follow-up of 12.9 months, grade 1-2 urinary tract infection, peripheral motor neuropathy, and hypogammaglobulinemia newly emerged, but the incidence of adverse events (AEs) did not increase notably during this follow-up period. No unexpected grade ≥ 3 treatment-related AEs were reported. Long-term oral monotherapy with tazemetostat showed favorable efficacy and safety profiles, indicating that it may be a useful third-line or later treatment option for patients with relapsed/refractory FL harboring the EZH2 mutation. Trial registration: ClinicalTrials.gov: NCT03456726.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11513718PMC
http://dx.doi.org/10.1007/s12185-024-03834-9DOI Listing

Publication Analysis

Top Keywords

ezh2 mutation
12
phase study
8
efficacy safety
8
patients relapsed/refractory
8
harboring ezh2
8
median follow-up
8
primary analysis
8
analysis median
8
follow-up
5
tazemetostat
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!